2002
 
 -Board approves for the allotment of 210,955 shares of the company at
 Rs.10 each to the share holders of Bombay Drugs & Pharmas Ltd.
 
 -Zenith Pharmaceuticals Ltd acquires 71% shares through preferential
 issue route.
 
 -Board approves for the proposal of restructuring its Cram division
 by hiving off into two separate company under the provisions of the
 companies act.
 
 -Incorporates 'Strides Africa Ltd' at British Virgin Island with an
 authorised capital of US $ 200,000 as 100% wholly owned subsidiary.
 
 -Board decides to change the name of the company to 'Strides Arcolab
 (FA)' to reflect the change in the business focus and operations.
 
 2003
 
 -Nominates Mr Francis Pinto as the Director on the Board of the
 company.
 
 -Forges an exclusive co-operation alliance with the South Africa
 based drug manufacturer Aspen Pharmacare, mainly to share the product
 development expertise and quality systems.
 
 -Concludes the strategic development and manufacturing agreement with
 Sorm Co. Ltd  for long term supply of Generics, OTC and Nutraceutical
 products.
 
 -Changes in the Management:
 Appoints Mr V Hariharan as CFO, Mr Joe Thomas as President, and Mr
 Krishna Kumar Menon as COO.
 
 -Board approves for the reorganization of subsidiaries of the company
 and for write off of dimunition in value of investments made in
 subsidiaries by the company.
 
 -Strides inks MoU with Ribbon SRL for Cephalosporin
 
 2004
 
 -Major Fire occurs in Private Custom Bonded warehouse in Mexico
 
 -Strides Arcolab Limited has entered into a memorandum of
 understanding with BITS, Pilani for an ``off campus collaborative
 programme''. As part of the partnership, Strides has launched a new
 initiative called STEP (Strides Training and Education Plan) intend
 to offer their employees an opportunity to acquire a MS in Pharma
 Operations & Management while on the job.
 
 2005
 
 - Enters into an agreement with Mayne Pharma Business Unit of
 Australia based Mayne Group Ltd, to develop and manufacture a range
 of six anti-infective products that Mayne will market and distribute
 in the US and European markets.
 
 -Strides Arcolab enters into an agreement for private placement
 issue
 
 - Strides Arcolab signs License Agreement with KV Pharma for
 exclusive marketing rights in the United States and Canada for 10 new
 generic drugs
 
 -Strides acquires sterile manufacturing facility in Poland
 
 2007
 
 -  Strides Arcolab has got tentative permission from the United
 States Food and Drug Administration (USFDA) for Efavirenz tablets, an
 anti-HIV drug. Efavirenz, is the generic version of Bristol Myers
 Squibb's Sustiva, which helps in preventing the HIV virus from
 reproduction.
 - Strides Arcolab receives 2 more NDA approvals from US-FDA.
 
 2008
 
 - Strides Arcolab Ltd on March 19, 2008 announced its third ANDA
 approval for Fosphenytoin Injection 50mg/mL in 2 ml and 10 ml vials.
 
 2010
 
 - Strides Arcolab Ltd has informed that Mr. V. S. Iyer has been
 appointed as an Executive Director of the Company.
 
 2011
 
 -Strides Arcolab Receives US FDA NOD To Commercialize First Sterlite
 
 
 -Strides announces First European Approval for Oncology Product
 
 -Strides Arcolab receives US FDA Nod to Commercialize First Liquid 
 
 -StridesArcoL Update on acquisition of outstanding minority
 shareholding in Ascent Pharmahealth Limited
 
 -Strides Arcolab joins the Malaysian Bio-xcell Ecosystem
 
 2012
 
 -Strides Arcolab Announces US FDA approval for its 'Brazilian Sterile
 
 
 -Strides Arcolab receives US FDA approval for Methotrexate Injection
 
 -Strides Arcolab Announces Health Canada Approval For Tobramycin
 Injection
 
 -Strides Arcolab acquires Sterile Formulations facility to expand
 core injectable biz
 
 -Strides collaborates with Gilead Sciences